Progresses in Pharmaceutical and Surgical Management of Premature Ejaculation
Premature ejaculation (PE) is one of the most common male sexual dysfunctions, affecting approximately 20% to 30% of the male population. It is associated with distress, anxiety, and negative impacts on relationships with sexual partners. This review provides a comprehensive overview of the definition, classification, etiology, and current treatment options for PE, focusing on pharmaceutical and surgical management.
Definition and Classification of PE
The definition of PE has been a subject of debate among various medical organizations. The American Psychiatric Association defines PE as a “persistent or recurrent ejaculation with minimal sexual stimulation prior or shortly after penetration and before the person wishes it.” The World Health Organization describes it as “the inability to delay ejaculation sufficiently to enjoy lovemaking, which is demonstrated by either an occurrence of ejaculation before or shortly after the beginning of intercourse, or an ejaculation that occurs in the absence of a sufficient erection to make intercourse possible.” The American Urological Association defines PE as “ejaculation that occurs sooner than desired, either before or shortly after penetration, causing distress to either one or both partners.”
The International Society for Sexual Medicine (ISSM) proposed a more evidence-based definition, considering three key factors: (1) short time interval between penetration and ejaculation, (2) lack of control over ejaculation, and (3) distress felt in one or both partners. The ISSM also introduced the intra-vaginal ejaculatory latency time (IELT) as an objective measure for evaluating PE.
PE is classified into four subtypes: lifelong PE (LPE), acquired PE (APE), natural variable PE, and subjective PE. Each subtype has distinct characteristics in terms of episodes, IELT, and etiology. LPE is present from the first sexual encounter, while APE develops after a period of normal ejaculation. Natural variable PE occurs randomly, and subjective PE is characterized by normal IELT but perceived as premature by the individual.
Physiology of Ejaculation
Ejaculation is a complex process controlled by both central and peripheral mechanisms. The peripheral control involves the pudendal sensory nerves, which transmit sexual stimulation signals to the spinal network. The spinal network processes these signals and converts them into motor and secretory outputs, leading to the contraction of pelvic and perineal muscles, resulting in ejaculation.
Central control of ejaculation is mediated by the cerebral network, which regulates the final output of ejaculatory stimuli. Neurotransmitters such as serotonin (5-HT), dopamine, acetylcholine, adrenaline, neuropeptides, oxytocin, gamma-aminobutyric acid (GABA), and nitric oxide play crucial roles in the regulation of the ejaculatory reflex. Among these, 5-HT is the most studied, with different receptor subtypes (e.g., 5-HT1a, 5-HT1b, 5-HT2c) influencing ejaculatory latency.
Etiology of PE
The exact causes of PE remain unclear, but it is believed to be influenced by a combination of psychological, somatic, and neurobiological factors. Genetic studies have suggested that polymorphisms in the serotonin transporter gene may be associated with PE. Other contributing factors include depression, erectile dysfunction, metabolic syndrome, chronic prostatitis, and thyroid dysfunction.
Treatment of PE
The management of PE involves behavioral and psychological therapy, pharmacotherapy, topical anesthetics, and surgical interventions. Each treatment option has its advantages and limitations.
Behavioral and Psychological Therapy
Behavioral therapy includes techniques such as the “stop-start” method and the “penis squeezing” technique. These methods aim to increase the ejaculation threshold and improve sexual self-confidence. However, evidence supporting the efficacy of psychological therapy alone is weak. Combining behavioral therapy with pharmacotherapy, such as dapoxetine, has shown better results in increasing IELT compared to drug treatment alone.
Pharmacotherapy
Pharmacological treatments for PE primarily target the central and peripheral control mechanisms of ejaculation. Selective serotonin reuptake inhibitors (SSRIs), serotonin-norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs), tramadol, phosphodiesterase type 5 (PDE-5) inhibitors, and alpha-blockers are commonly used.
Selective Serotonin Reuptake Inhibitors (SSRIs)
SSRIs are the mainstay of pharmacotherapy for PE, particularly LPE. They increase serotonin neurotransmission, which helps delay ejaculation. Commonly used SSRIs include dapoxetine, fluoxetine, paroxetine, sertraline, and citalopram. Dapoxetine, specifically designed for PE, has a fast absorption and short half-life, making it suitable for on-demand use. Clinical trials have demonstrated its efficacy in increasing IELT, although high dropout rates due to side effects and cost are concerns.
Serotonin-Norepinephrine Reuptake Inhibitors (SNRIs)
SNRIs, such as duloxetine, have also shown promise in treating PE. Studies comparing duloxetine with paroxetine found similar efficacy in increasing IELT, with both drugs being well-tolerated.
Tricyclic Antidepressants (TCAs)
Clomipramine, a TCA, has been used to treat PE by inhibiting serotonin and norepinephrine reuptake. It has shown efficacy in increasing IELT, but side effects such as fatigue, nausea, and dry mouth limit its use.
Tramadol
Tramadol, an opioid analgesic, has been investigated for its potential to delay ejaculation. Clinical trials have shown that tramadol significantly increases IELT, with higher doses providing greater efficacy. However, the risk of addiction and abuse necessitates cautious use.
Phosphodiesterase Type 5 (PDE-5) Inhibitors
PDE-5 inhibitors, such as tadalafil, are primarily used to treat erectile dysfunction but have also been found to improve PE, especially in patients with comorbid erectile dysfunction. Combination therapy with SSRIs or topical anesthetics has shown enhanced efficacy but may increase the risk of side effects.
Alpha-Blockers
Alpha-blockers, such as silodosin and naftopidil, have been used to treat PE by inhibiting the contraction of smooth muscles involved in ejaculation. Silodosin has shown higher efficacy in increasing IELT compared to naftopidil.
Topical Anesthetics
Topical anesthetics, such as eutectic mixture of local anesthetics (EMLA), topical eutectic mixture for premature ejaculation (TEMPE), and severance secret (SS) cream, are applied to the penis to reduce hypersensitivity and delay ejaculation. These agents have shown efficacy in increasing IELT but may cause numbness and decreased sensation in sexual partners.
Surgical Treatment
Surgical interventions for PE are considered for patients who are resistant to pharmacotherapy. Procedures such as selective penile dorsal nerve neurotomy (SDN), cryoablation, radiofrequency therapy, and glandular augmentation with hyaluronic acid gel have been explored.
Selective Penile Dorsal Nerve Neurotomy (SDN)
SDN involves the surgical removal of branches of the dorsal penile nerve to reduce hypersensitivity and increase IELT. Studies have shown significant improvements in IELT following SDN, although the procedure is not widely accepted due to concerns about potential complications and long-term efficacy.
Cryoablation and Radiofrequency Therapy
Cryoablation and pulsed radiofrequency therapy are minimally invasive techniques that target the dorsal penile nerve to reduce hypersensitivity. These methods have shown promise in increasing IELT, with fewer complications compared to surgical interventions.
Glandular Augmentation with Hyaluronic Acid Gel
This procedure involves injecting hyaluronic acid gel into the glans penis to create a barrier between the dorsal penile nerve and external stimuli. While some studies have reported efficacy, concerns about sensory loss and other complications limit its widespread use.
Controversies in Surgical Treatment
Surgical treatments for PE remain controversial due to insufficient evidence supporting their long-term efficacy and safety. While some practitioners advocate for these procedures as an alternative to pharmacotherapy, others caution against their use until more robust clinical data are available.
Conclusion
PE is a complex condition with multiple contributing factors. Current treatment options, including pharmacotherapy, behavioral therapy, topical anesthetics, and surgical interventions, have shown varying degrees of efficacy. SSRIs remain the mainstay of pharmacotherapy, while surgical options are considered for treatment-resistant cases. However, all treatments have limitations, and further research is needed to develop more effective and safer therapies for PE.
doi.org/10.1097/CM9.0000000000000433
Was this helpful?
0 / 0